Skip to main content

Table 5 Descriptive statistics of primary outcome measured at baseline, 3-month, 9-month and 15-month after start of intervention and treatment effects as changes from baseline compared between groups

From: Is tailored treatment superior to non-tailored treatment for pain and disability in women with non-specific neck pain? A randomized controlled trial

  TT NTT TAU TT vs NTT TT vs TAU NTT vs TAU
Estimated mean (SD) Estimated mean (SD) Estimated mean (SD) Effectsb
(95 % CI)
Effectsb
(95 % CI)
Effectsc
(95 % CI)
NRS
 Baseline 4.55 (2.08) 4.57 (2.08) 4.72 (2.08)    
 3 month 2.62 (2.04) 2.56 (2.04) 3.97 (2.04) −0.09
(-0.48 to 1.5)
1.17
(0.15 to 2.19)*
1.26
(0.27 to 2.25)*
 9 month 2.85 (2.04) 3.31 (2.04) 3.5 (2.07) 0.43
(-1.55 to 2.41)
0.47
(-0.52 to 1.46)
0.04
(-0.95 to 1.03)
 15 month 3.06 (2.04) 2.85 (2.04) 3.6 (2.07) −0.24
(-2.22 to 1.74)
0.41
(-0.58 to 1.4)
0.65
(-0.34 to 1.64)
NDI
 Baseline 21.84 (10.18) 24.39 (10.18) 24.18 (10.05)    
 3 month 14.62 (9.85) 14.39 (9.96) 21.74 (9.93) −2.78
(-6.85 to 1.29)
4.78
(0.67 to 8.89)*
7.56
(3.49 to 11.63)***
 9 month 14.84 (9.85) 16.61 (9.96) 19.65 (9.93) −0.78
(-4.87 to 3.31)
2.47
(-1.64 to 6.58)
3.25
(-0.82 to 7.32)
 15 month 15.20 (9.85) 13.80 (9.96) 17.99 (9.94) −3.95
(-8.02 to 0.12)
0.45
(-3.64 to 4.54)
4.40
(0.35 to 8.45)*
  1. TT tailored treatment, NTT non-tailored treatment, TAU treatment as usual group, vs versus, SD standard deviation, CI confidence interval, NRS Average pain intensity last week (0-10), NDI neck disability index (0-100); b Positive values of effects favor the tailored group; c Positive values of effects favor the non-tailored group; * comparison is significant at the 0.05 level. ** comparison is significant at the 0.01 level. *** comparison is significant at the 0.001 level